Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.

Liquidating its stake in Arrowhead helps Sarepta cover a milestone payment and secure what one analyst described as ...

Sarepta’s troubles had nothing to do with Arrowhead’s assets, and yet both companies have seen their stock prices decline ...

The milestone payment is partially funded through Sarepta’s Arrowhead stock sale as both companies push forward with ...

Sarepta Therapeutics is selling off Arrowhead Pharmaceuticals’ shares to stretch its cash runway, while also inking a share ...

Sarepta Therapeutics sells 9.3M Arrowhead shares for $174M and fulfills a $100M milestone payment. Read more here.

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Sarepta Therapeutics said Friday that the deaths of two patients taking its marketed gene therapy Elevidys® (delandistrogene ...

In the wake of multiple patient deaths from liver injuries related to Sarepta Therapeutics’ AAV gene therapy platform, some ...

Sarepta Therapeutics, the US biotech, has sold around 9.3 million shares of Arrowhead Pharmaceuticals in a privately ...

The stock has been in free fall since safety issues derailed a gene therapy analysts had expected to achieve blockbuster ...

A well-connected drug company and Laura Loomer wanted Kennedy ally Vinay Prasad gone. Trump chief of staff Susie Wiles got ...